28-Oct-07
-- Joint Breakfast Meeting of the JDM Working Group and IMACS*
-- Saturday November 10, 2007; Time: 6:45 - 9:00 AM
-- Location: The Westin Boston Waterfront - Room: Commonwealth Ballroom Section A & B
AGENDA
| 0645 Breakfast Service begins |
|
| 0700 - 0745 MYOSITIS RESEARCH UPDATES Moderators: Drs. Bianca Lang and David Isenberg |
|
| 1. Cure JM | Ms. Jacquelyne DenUyl |
| 2. The Myositis Association | Mr. Bob Goldberg |
| 3. CARRA - JDM Practice Survey | Dr. Brian Feldman |
| 4. PRINTO JDM Trial | Dr. Nicola Ruperto |
| 5. JDM Diagnostic Criteria Study | Dr. Clarissa Pilkington |
| 6. Myositis Classification Criteria Project | Dr. Ingrid Lundberg |
| 7. Etanercept for Dermatomyositis Trial | Dr. Anthony Amato |
| 8. Rituximab in Myositis (RIM) Trial | Dr. Chester Oddis |
| 9. MITAX Computer Program | Dr. David Isenberg |
| 10. IMACS Trials Repository | Drs. Lisa Rider and Fred Miller |
| 0745 - 0900 MINISYMPOSIUM "THE ROLE OF INTERFERONS IN MYOSITIS PATHOGENESIS" Moderators: Drs. Frederick Miller and Lisa Rider |
|
| 1. Dendritic Cells in the Pathogenesis of Juvenile Dermatomyositis | Dr. Ann Reed |
| 2. Scientific Rationale for the Interferon-Alpha Blockade in DM/PM | Dr. Steven Greenberg |
| 3. Endogenous Activation of the Type I Interferon System in Myositis - A role for Anti-Jo 1 or Anti-Ro? | Dr. Ingrid Lundberg |
| 4. Interferon response in JDM vs. SLE | Dr. Virginia Pascual |
| 5. Relationship of Interferon Gene Expression to Disease Activity and Duration | Dr. Lauren Pachman |
| 6. Anti-interferon alpha as a treatment for idiopathic inflammatory myopathy | Dr. Gregory Dennis |
The generous support of sponsors Wyeth/Amgen, The Myositis Association and the Cure JM Foundation is appreciated.
to Top